Diagnostic Nano Technology Corporation (DNA), a subsidiary of Avisio, Inc. (PINKSHEETS: AVIC), reports with the early laboratory success of its Instant Detect Technology in the detection of certain viruses that cause Dengue Fever, it plans to begin testing the technology on the detection of the H1N1 virus.
"Ongoing testing of this type is a necessary component in the process of selecting DNA's initial human application development projects," said Amro Albanna, CEO of DNA and Avisio, Inc. "We are cautiously optimistic about the market opportunity that exists for DNA's Instant Detect product, especially with regard to potential human applications. We realize that we are early in the process and still have a number of milestones to reach, including but not limited to further proof of concept, the ability to produce product at scale, third-party validation and regulatory approvals, before we can begin to market a product," continued Albanna.
Avisio, Inc. is a publicly-traded technology commercialization company with a mission to unlock the value of high-potential assets and transform them into high-value businesses. Avisio plans to create a new majority-owned private subsidiary around each asset and to support each business with experienced management teams, best-of-breed commercialization processes and resources, and access to global capital sources.
For more information, please visit www.avisioinc.com
Contact:
(951) 786-9474 x221
